Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

'Jekyll and Hyde' Protein Offers New Route to Cancer Drugs

Published: Friday, September 27, 2013
Last Updated: Friday, September 27, 2013
Bookmark and Share
The mood changes of a 'Jekyll-and-Hyde' protein, which sometimes boosts tumour cell growth and at other times suppresses it, have been explained.

The researchers in Britain, with collaborators in Singapore and the USA, carried out a comprehensive biological study of the protein E2F, which is abnormal in the vast majority of cancers. They were able to explain the dual natures it can take up in cells in the body, and indicate how it could be a potent target for developing new cancer drugs.

The Oxford University scientists have since carried out a drug-discovery screen, and shown that compounds which block the protein’s change into 'Mr Hyde' result in the death of cancer cells.

'This mechanism for switching a key protein is very novel. Nothing else I’ve come across behaves like it,' says Professor Nick La Thangue of the Department of Oncology at Oxford University, who led the work. 'Subtle changes in terms of the chemistry of the protein have dramatic and polar opposite effects on the tumour cell, either allowing them to continuously grow or switching them to cell death mode.

'We are excited by this new discovery, which provides a new and very important approach to developing new types of cancer drugs. We have much work to do,' says Professor La Thangue.

The researchers from the University of Oxford, the Genome Institute of Singapore and the University of Texas' MD Anderson Cancer Centre in the USA report their findings in the journal Molecular Cell. The study was part-funded by the UK Medical Research Council and Cancer Research UK.

Cells in the body go through cycles of growth and division, pauses and death in a highly regulated way. Cancer involves the breakdown of these controls leading to unlimited expansion of the cells in a growing tumour.

The protein E2F is inextricably linked to cancer. It is normally tightly controlled in the cell cycle, but in most if not all cancer cells the processes E2F oversees go awry so that it keeps cells growing.

Puzzlingly, while it can be a factor driving cancer, on other occasions E2F is protective and removes damaged cells. When normal cells experience damage, E2F is involved in switching the cell towards cell death in a process called apoptosis. This helps prevent the build up of DNA errors and the development of cancer.

It’s this dual Jekyll-and-Hyde nature of E2F that the researchers have been able to explain for the first time.

They show that E2F is an important switch that determines cell fate. As Dr Jekyll, when DNA damage is detected, it leads to cell death. As Mr Hyde, it switches on cell growth and proliferation – and in most if not all cancers, it is this function of E2F that becomes out of control.

The researchers show that two enzymes compete to attach a molecular label, or flag, on different parts of the E2F protein. The flag in one position sees E2F act to cause cell death and the same flag in another position see E2F boost cell growth and proliferation.

Professor La Thangue says: 'It's like there’s an angel and a devil competing to get on each shoulder of the protein. Which one gets the upper hand is able to whisper in the ear of the protein and tell it what it should do. With the molecular flag on one shoulder, E2F goes into cell kill mode. With the flag on the other, it goes into cell growth mode. The challenge is to mimic this process with drugs, and reinstate the death pathway in tumour cells.'

In cancer cells, E2F gets stuck with the flag boosting growth and division, helping drive the tumour's growth. The researchers identified another protein in the cell which looks for the presence of this flag.

'Blocking this protein means the devil's whispers never get heard and E2F doesn't transform into Mr Hyde,' says Professor La Thangue. 'Instead, E2F switches over to cell-death mode and the cancer cells die out.

'We've identified compounds – drug candidates - that do exactly that,' he explains.

Dr Shunsheng Zheng, first author of the study and a graduate student on the joint A*STAR-University of Oxford DPhil scholarship programme, said: 'E2F is a tricky protein to work with. Normal cells use it for growth, cancer cells need it for hypergrowth, but too much of it seems to drive cancer cells into suicidal mode.'

Dr Kat Arney, science information manager at Cancer Research UK, which part-funded the work, said: 'Cancer is a complex biological problem, and getting to grips with the molecules that drive it is essential if we're to find new cures. Although there's a lot more work to be done before this new discovery could become a treatment for patients, this research is an important step forward in understanding E2F’s "split personality" in both driving and destroying cancer cells.'


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

HIV Keeps Growing, Even When Undetectable
A team of international researchers including scientists from Oxford University has found that HIV is still replicating in lymphoid tissue even when it is undetectable in the blood of patients on antiretroviral drugs.
Friday, January 29, 2016
Bacterial Superglue for Faster Vaccine Development
An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.
Wednesday, January 20, 2016
Millions at Risk of Little Known Deadly Tropical Disease
Melioidosis, a difficult to diagnose deadly bacterial disease, is likely to be present in many more countries than previously thought.
Tuesday, January 12, 2016
Identifying Drug Resistance Traits
Scientists have developed an easy-to-use computer program that can quickly analyse bacterial DNA from a patient's infection and predict which antibiotics will work, and which will fail due to drug resistance.
Tuesday, December 22, 2015
Faster, Cheaper TB Diagnosis
Whole Genome Sequencing is a faster, cheaper and more effective way of diagnosing tuberculosis says a new study.
Wednesday, December 09, 2015
Why we Still Don’t Have Personalised Medicine
15 years after sequencing the human genome we still do not have the promised personalised medicine, why is this?
Friday, December 04, 2015
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Tuesday, November 24, 2015
Seeking the Right Prescription in Fight Against Antibiotic Resistance
Researchers at the University of Oxford have received funding to look at ways to improve the prescribing of antibiotics.
Monday, November 23, 2015
£17M Project Launched to Develop HIV Vaccine
A new €23 million (£17 million) initiative to accelerate the search for an effective HIV vaccine has begun.
Wednesday, November 11, 2015
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Tuesday, November 10, 2015
Mini DNA Sequencer’s Data Belies its Size
A miniature DNA sequencing device that plugs into a laptop and was developed by Oxford Nanopore has been tested by an open, international consortium, including Oxford University researchers.
Tuesday, October 20, 2015
Microbe Artwork Shows The Limits Of Antibiotics
An Oxford University research fellow has been creating art using bacteria found in the human gut and harvested from faecal samples.
Tuesday, September 29, 2015
Funding Boost for Diabetes Research
Programme of research could be a game-changer for people with Type 1 diabetes and insulin-dependent Type 2 diabetes.
Friday, July 24, 2015
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
Thursday, July 16, 2015
New Insight into Recombination and Sex Chromosomes
Not only does the platypus have some odd physical features, an updated version of its genome has also underscored the unusual genetic characteristics that it harbors.
Tuesday, May 12, 2015
Scientific News
Microdroplet Reactors Mimic Living Systems
Researchers use microdroplets to study non-equilibrium reactions like those in living organisms.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
The Spice of Life
Scientists discover important genetic source of human diversity.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
The Power of Three
Overlooked portion of cell “death receptor” critical in some cancers, autoimmune diseases.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Removing Race from Human Genetic Research
A group of scientists are urging their colleagues to take a step forward and stop using racial categories when researching and studying human genetics.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!